Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Poble (Le Plessis-Robinson, France), C. Phan (Le Plessis-Robinson, France), T. Quatremare (Le Plessis-Robinson, France), J. Bordenave (Le Plessis-Robinson, France), R. Thuillet (Le Plessis-Robinson, France), A. Cumont (Le Plessis-Robinson, France), A. Huertas (Le Plessis-Robinson, France), P. Dorfmüller (Le Plessis-Robinson, France), L. Tu (Le Plessis-Robinson, France), M. Humbert (Le Plessis-Robinson, France), M. Ghigna (Le Plessis-Robinson, France), C. Guignabert (Le Plessis-Robinson, France). Pirfenidone protects against pulmonary hypertension in the Sugen5416/hypoxia rat model. 274

Member's Comments

No comment yet.

Related content which might interest you: Two rat models of hemolysis-induced pulmonary hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Reversibility of the monocrotaline pulmonary hypertension rat model Source: Eur Respir J 2013; 42: 553-556 Year: 2013 Bevacizumab administration in monocrotaline induced pulmonary arterial hypertension rat model Source: Annual Congress 2010 - Pulmonary vascular diseases Year: 2010 Inflammatory changes in a murine model of monocrotaline-induced pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 365s Year: 2005 Reversal of pulmonary hypertension in a sugen/hypoxic rat model using an ASK1 inhibitor Source: International Congress 2017 – New perspectives from experimental models of pulmonary hypertension Year: 2017 2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008 ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 VIP greatly attenuates monocrotaline-induced pulmonary vasculopathy in rats Source: Annual Congress 2009 - Pathobiology of pulmonary hypertension Year: 2009 2-Ethoxyestradiol inhibits vascular and cardiac remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 R-Crizotinib predisposes to and exacerbates pulmonary arterial hypertension in animal models Source: Eur Respir J, 57 (5) 2003271; 10.1183/13993003.03271-2020 Year: 2021 Neutralization of CXCL12 reverses established pulmonary hypertension in the sugen-hypoxia rat model Source: International Congress 2017 – Experimental PH Year: 2017 A novel murine model of severe pulmonary arterial hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Effect of fasudil on the bleomycin-induced pulmonary fibrosis and hypertension in mice Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms Year: 2012 Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Bevacizumab administration in pulmonary arterial hypertension rat model decondary to chronical hypoxia exposure Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Genistein rescues pulmonary hypertension and attenuates abnormal vasoconstriction in rats lungs Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats Source: Eur Respir J 2011; 37: 1104-1118 Year: 2011 Effect of roflumilast on hypoxia- and monocrotaline-induced pulmonary hypertension in rats Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair Year: 2007 Regulation of connexins by hypoxia in rat pulmonary vascular cells in an in vitro model of pulmonary hypertension Source: International Congress 2017 – Experimental PH Year: 2017 Ambrisentan attenuates lung and heart injury in a rat model of bronchopulmonary dysplasia Source: Annual Congress 2011 - The ageing pulmonary interstitium Year: 2011